Neoadjuvant Combination Therapy with Tyrosine Kinase and Immune Checkpoint Inhibitors in Anaplastic Thyroid Cancer: A Single-Center, Real-World Experience
- 3 April 2026
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (7) , 5950-5957
Abstract
Most patients with anaplastic thyroid carcinoma (ATC) present with surgically unresectable disease. The use of combined kinase inhibitors and immunotherapyKeywords
Funding Information
- Clinical research fund for distinguished young scholars of Beijing Cancer Hospital
This publication has 23 references indexed in Scilit:
- Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: A retrospective single-center studyOral Oncology, 2024
- Initial Management of BRAF V600E-Variant Anaplastic Thyroid CancerJAMA Oncology, 2024
- Neoadjuvant therapy to improve resectability of advanced thyroid cancer: A real‐world experienceHead & Neck, 2024
- Efficacy and safety of anlotinib-based chemotherapy for locally advanced or metastatic anaplastic thyroid carcinomaEndocrine, 2023
- 1646MO Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinomaAnnals of Oncology, 2022
- Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket studyAnnals of Oncology, 2022
- Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid CarcinomaThyroid®, 2021
- Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: A prospective blinded single center study in ChinaCancer Medicine, 2020
- Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
BRAF
V600E
-Mutated Anaplastic Thyroid CarcinomaThyroid®, 2019
- American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid CancerThyroid®, 2012